Background and Aim: As society ages, the need for endoscopic retrograde cholangiopancreatography (ERCP) is increasing. This prospective comparative study evaluated the safety and efficacy of midazolam-versus propofol-based sedations by non-anesthesiologists during therapeutic ERCP in patients over 80 years of age.
INTRODUCTION
A S A RESULT of increases in expected survival and improvements in general performance status, the need for therapeutic endoscopic retrograde cholangiopancreatography (ERCP) in pancreaticobiliary diseases may be increasing. For a successful and safe ERCP, conscious sedation as well as technical significance for ERCP should be carried out carefully in patients aged 70 years and older. Technically, ERCP is efficacious and safe even in patients 80 years and older. ERCP in older patients may take a longer time because of increased interventions, such as stent insertion or multiple stone removal, and requires less sedation. However, the known overall complication and mortality rates are comparable to those of younger patients.
may delay the metabolism of fat-soluble benzodiazepine and, in turn, markedly increase the clinical effect of the sedative drugs. Furthermore, lower renal and hepatic functions reduce drug metabolism, which is why cardiopulmonary complications occur more frequently in older patients even when a standard dose of sedative hypnotic is used. [13] [14] [15] Therefore, the half-lives of sedatives for older patients should be as short as possible, with a small dose for slow titration, and a minimal cumulative dose should be used.
Among the effective sedatives, propofol, which has a narrow safety margin, should be used with care in older patients. It is advisable to start with half of the dose given to healthy adults. Common adverse effects of propofol are reduced vasoconstriction of the blood vessels supplying the heart, thereby lowering cardiac output, systemic vascular resistance and arterial pressure; and respiratory inhibition, which can improve rapidly once i.v. injection is discontinued. Another limitation is that no propofol antagonist is yet available.
14 However, recent European guidelines state that propofol can also be safely applied in older patients by nonanesthesiologists. Giving propofol by nurses or endoscopists is commonly referred to as non-anesthesiologist-administered propofol (NAAP). 16 In some countries, including South Korea, most endoscopies, including therapeutic ERCP and interventional endoscopic ultrasonography, are done under conscious sedation by NAAP. Anesthesiologist-directed sedation is carried out under limited conditions such as in patients with a high American Society of Anesthesiologist (ASA) class or in a small number of hospitals. However, use of propofol in NAAP is still questionable as a result of safety concerns, especially in very elderly patients, although the complication rate of propofol was comparable to those of other agents according to a systematic review. 16, 17 The frequency of NAAP use is increasing in several countries. Conscious sedation by NAAP has been reported to be safe and tolerable, as well as less costly. 6, 16, [18] [19] [20] However, an adequate sedation protocol for patients over 80 years of age is still required under non-anesthesiologist directed sedation.
This prospective comparative study investigated the safety, efficacy, and satisfaction of patients according to midazolam-or propofol-based sedation with fentanyl, given by non-anesthesiologists during ERCP, in patients over 80 years of age.
METHODS

C
ONSECUTIVE PATIENTS OVER 80 years of age with a na€ ıve papilla who were scheduled for therapeutic ERCP were recruited from March 2014 to August 2016. Exclusion criteria were uncontrolled coagulopathy, ASA Class V, a known allergy to the drugs used in this study, a history of complications from a previous sedation, sedative or alcohol abuse, and inability to provide informed consent. The institutional review board approved the study protocol, and written informed consent was obtained from all enrolled patients. The protocol has been registered at Clinical Trials Registry (UMIN-25385), and follows Consolidated Standards of Reporting Trials (CONSORT) guidelines.
The computer-generated allocation sequence was assigned to each patient at the time of sedation induction. A separate nurse who did not participate in the survey injected the sedation regimen and monitored the patients. An endoscopist and another primary assistant nurse began the endoscopic procedures after a moderate level of sedation had been reached. Finally, the primary assistant nurse and endoscopist, who were blinded to the sedation protocol, participated in the survey.
The sedation protocol was modified from our previous studies as follows. 19, 20 (i) In the midazolam + fentanyl (MF) group, both midazolam (0.05 mg/kg bodyweight or 1 mg) and fentanyl (12.5-50 lg) were given intravenously (i.v.) at the start of sedation. Thereafter, repeated doses of 0.5-1 mg midazolam were given to achieve and maintain a moderate level of sedation. (ii) In the propofol + fentanyl (PF) group, sedation was induced by an i.v. bolus injection of propofol (0.5 mg/kg bodyweight or 10 mg) and fentanyl (12.5-50 lg). Repeated doses of 5-10 mg propofol were then given to maintain adequate sedation. The target level of sedation was moderate based on the ASA criteria and a modified assessment of alertness/sedation score of 3 in both groups. 21 Initial vital signs of all patients were checked before sedation, and heart rate, blood pressure, and oxygen saturation were monitored continuously from the start of sedation to full recovery after completion of the endoscopic procedures. Intranasal supplemental oxygen (2 L/min) was provided to all patients prior to start of sedation. All monitoring parameters and sedation levels were recorded by trained sedation nurses every 5 min or when the patient was awake, irritable or unstable.
ERCP was carried out using a standard duodenoscope (TJF 240 or 260V; Olympus Optical Co., Ltd, Tokyo, Japan) in the prone or left-side position. For insufflation, CO 2 gas was provided by a commercially available CO 2 regulator used in endoscopic procedures (ENDO CO2 PRO-500; MIRAE Medics, Seoul, Korea). All endoscopic procedures were carried out by two experienced endoscopists who were faculty at the hospital and assistant nurses technically trained in endoscopy. Trainees were not involved in the therapeutic ERCP procedures.
Outcome definition and measurements
Primary outcome measured was sedation safety according to cardiopulmonary components. Sedation safety was assessed in terms of cardiopulmonary complications, including systolic hypotension (systolic blood pressure <90 mmHg), bradycardia (heart rate <50 b.p.m.), hypoxia (pulse oximetry-measured oxygen saturation [SpO 2 ] <90% on supplemental oxygen), and permanent injury or death. If the SpO 2 decreased to <90%, the nasal oxygen supply was increased by 2 L/min until returning to a normalized oxygen saturation. If the SpO 2 decreased to <85% for >30 s, despite an increase in supplemental oxygen supply and jaw thrust, the procedure was interrupted and the endoscope withdrawn until a normalized oxygen saturation was achieved. The endoscopic procedure was re-attempted after the patient had stabilized.
Sedation efficacy was based on satisfaction analysis, induction time, and recovery time. The overall satisfaction with endoscopic sedation of patients, endoscopists, and nurses was measured using a 10-cm visual analogue scale (VAS). Satisfaction with endoscopic sedation of the patients was measured after full recovery in an inpatient setting. All patients used the 10-cm VAS to complete a questionnaire regarding overall satisfaction with the sedation and procedures. The endoscopists and assistant nurses also used the 10-cm VAS to complete a questionnaire inquiring about overall satisfaction with endoscopic sedation, including patient cooperation and difficulty with sedation maintenance (ranging from 0 = poor to 10 = excellent). Sedation induction time was measured from the first injection of sedative drugs to the onset of effective sedation. Full recovery time was measured from the completion of the ERCP procedures to achievement of a modified Aldrete score of 10. 22 Criteria for discharge from the endoscopy recovery unit to the inpatient ward was when the patient reached a modified Aldrete score of 10.
Therapeutic procedure outcomes, including technical success rate and procedure time, and procedure-related complications were measured. If transient interruptions of the procedure occurred because of sedation-related adverse events, that time was subtracted from the total procedure time. All ERCP-related complications were classified and graded according to consensus guidelines. 23 
Statistical analysis
Data are expressed as means AE standard deviation (SD) or numbers (%). Chi-squared test or Fisher's exact test was used to compare categorical data and the t-test or Mann- 
RESULTS
D
URING THE ENROLMENT period, 109 patients over 80 years of age were enrolled. Among them, nine patients were excluded because of previous sphincterotomy (n = 4), previous surgical choledochoduodenostomy (n = 2), uncontrolled coagulopathy (n = 1), or previous sedation-related complications (n = 2) (Fig. 1) . A total of 100 patients (52 males) 80 years or older were finally enrolled and evaluated. Mean patient age was 84 years in the MF group and 83 years in the PF group. Body mass index, comorbid diseases, ASA class, indication for therapeutic ERCP, and baseline vital signs were not different between the two groups. The most frequent comorbid disease and indication were cardiopulmonary disease and choledocholithiasis, respectively (Table 1) .
Regarding primary outcome, overall cardiopulmonary adverse events occurred in 12 patients (24%) in the MF group and in 11 patients (22%) in the PF group (P = 0.812). However, in the PF group, three patients exhibited hypoxia with tachycardia (n = 2) or hypotension (n = 1). Systolic hypotension developed in two patients (4%) in the MF group and in three patients (6%) in the PF group (P = 0.648). Hypoxia occurred in seven patients (14%) in the MF group and in eight patients (16%) in the PF group (P = 0.779). Increased O 2 supply was given more frequently in the PF group than in the MF group (32% vs 42%), albeit not significantly so (P = 0.3). Temporary interruption of procedures occurred in two patients in the MF group and in three patients in the PF group (P = 0.648). However, permanent interruption of the procedure or mortality did not occur in either group (Table 2) .
Mean sedation induction times were 3.57 min in the MF group and 3.60 min in the PF group (P = 0.953). Mean recovery times after completion of the endoscopic procedures were 17.91 min and 14.11 min in the MF and PF groups, respectively (P < 0.001). The PF group had a shorter recovery time. Mean dose of midazolam given in the MF group was 6.37 mg, and that of propofol in the PF group was 125.1 mg. Mean doses of fentanyl were 23.7 lg and 22.5 lg in the MF and PF groups, respectively (P = 0.164). Regarding satisfaction with sedation, mean patient satisfaction score for sedation was 8.94 in the MF group and 8.8 in the PF group (P = 0.680). A sense of pain during the procedures was experienced by five and six patients, with mean pain scores of 4.0 and 3.67, in the MF and PF groups, respectively (P = 0.557). Mean satisfaction scores of the endoscopists and nurses were not different between the two groups (Table 3) .
Technical success rate of ERCP was 100% in both groups. The most frequent endoscopic procedures were extraction of common bile duct stones (46% and 54% of patients in the MF and PF groups, respectively), followed by insertion of a plastic stent. Mean procedure times were 24 min and 28 min in the MF and PF groups, respectively (P = 0.299). Rate of ERCP-related adverse events did not differ between the two groups. Mild post-ERCP pancreatitis occurred in two patients in the MF group (P = 0.495) ( Table 4 ). There were no serious complications or mortalities.
DISCUSSION
T HERAPEUTIC ERCP IN patients 80 years and older is considered an effective technique without an increase in complications compared to that in younger patients. 3, [8] [9] [10] [11] However, the method of endoscopic sedation differs according to country, health-care system, cost, and preference. In general, propofol-based sedation exhibits adverse event rates similar to those of benzodiazepines and provides better sedation quality, greater patient cooperation, and higher post-procedural patient satisfaction for most endoscopic procedures. 6, [18] [19] [20] In addition, for advanced endoscopic procedures, compared with sedation by an anesthesiologist, NAAP has a similar level of safety but potentially lower patient and endoscopist satisfaction. 16 Anesthesiologist-assisted sedation is costly and may be restricted by medical circumstances and the health-care system. Therefore, propofol-based sedation by non-anesthesiologists, such as endoscopists or trained nurses, can be a useful alternative.
However, data regarding the efficacy and safety of endoscopic sedation in patients over 80 years of age are still limited. Also, giving propofol is restricted to endoscopists or trained nurses in some countries because of the risks of cardiopulmonary decompression, absence of an antidote, and drug abuse. Especially, patients 80 years and older have more comorbid cardiopulmonary diseases and potentially compromised cardiopulmonary function. In such patients, endoscopic sedation should be done with caution, particularly with regard to the drug(s) and method selection.
In the general population, endoscopic sedation based on balanced propofol sedation during therapeutic ERCP showed better sedation efficacy in terms of improved patient cooperation and patient satisfaction and decreased recovery time, compared with propofol monosedation. There was no significant difference in the rates of adverse events. 6, [18] [19] [20] Therefore, propofol-based sedation was more efficacious with a similar safety profile during advanced endoscopic procedures compared with midazolam-based sedation. In NAAP, propofol-based sedation may be feasible even for advanced endoscopic procedures. However, as a result of the narrow safety margin of propofol, traditional sedation (such as midazolam) may be more efficacious and safer in elderly patients over 80 years.
The present study investigated the efficacy and safety of midazolam-and propofol-based sedation according to our endoscopic sedation protocols in patients over 80 years of age. We injected midazolam or propofol according to bodyweight or by a stepwise increase in dose, followed by fentanyl as an analgesic to enhance sedation. In our previous studies, meperidine was used. However, fentanyl is a highly lipid-soluble and synthetic opioid narcotic that is preferred over meperidine owing to its shorter duration of action and fewer side-effects. 24, 25 Therefore, fentanyl may be more appropriate for older patients than meperidine. In addition, when combined with a monoamine oxidase inhibitor, fentanyl does not induce serious drug interactions and is less associated with cardiovascular adverse effects. 13 Also, in our previous study, the sense of pain score during the procedure was higher in those who received propofol monosedation without analgesics such as meperidine or fentanyl (P < 0.001). 20 For this reason, we injected fentanyl after injection of midazolam or propofol in both groups.
Our data show that midazolam-and propofol-based sedation is safe and effective in very elderly patients under careful monitoring by assistant nurses. Overall cardiopulmonary complication rates were not different between the two groups. However, combined complications, such as hypoxia with tachycardia (n = 2) or hypotension (n = 1), developed only in patients who underwent propofol-based sedation. The frequency of hypoxia was not different between the two groups. However, the frequency of hypoxia (15%) was higher than that in our previous study (2.9-10%), and no serious complications or permanent interruption of the procedures occurred. 19, 20 Increased O 2 supply during sedation was more frequent in the PF group, albeit not significantly so. Although the total dose of propofol was lower than that in previous studies as a result of lower bodyweight or advanced age, there was no difference in patient, endoscopist, or nurse satisfaction with sedation efficacy.
Based on this and our previous studies, [18] [19] [20] midazolam-based sedation with fentanyl may be recommended for safe endoscopic sedation given by non-anesthesiologists in patients over 80 years of age. Midazolam-based sedation showed the same sedation quality and satisfaction as those of propofol-based sedation, with the exception of recovery time. MF sedation showed a tendency towards decreased frequencies of supplemental O 2 and combined cardiopulmonary complications; however, there was no difference in overall satisfaction with sedation. Addition of fentanyl may enhance the sedative and analgesic effects, possibly leading to increased patient satisfaction, compared with propofol monosedation, without increasing the dose of propofol. Also, the availability of an antidote for midazolam may exert a positive psychological effect on endoscopists. However, there was no significant difference in safety or efficacy between the two methods. Regardless, propofol-based sedation showed more benefits than did midazolam-based sedation in the general population.
The first limitation of the present study was the relatively small number of patients recruited from a single tertiary center in a restricted area of Asia. Although this study focused on sedation safety and efficacy in elderly patients undergoing therapeutic ERCP using different sedation protocols, further large-sized research is warranted. Furthermore, additional statistical power calculations and analysis for cost-effectiveness are needed to support our results. Second, although the endoscopists and nurses participating in the survey were blinded to the sedation protocol, complete blinding to repeated injection of sedation drugs was not possible. This might have resulted in a bias in the survey results. Third, a total of 10% of patients were oversedated without a difference between the two groups. However, more episodes of deep sedation might have gone undetected, as we were unable to carry out continuous assessment of sedation. We assessed at regular intervals by a single independent observer. Continuous monitoring system is needed to overcome this limitation. Fourth, positioning the patients during ERCP may have a bearing on cardiopulmonary events. In our practice of ERCP, primary position during ERCP was a prone position, but in patients with disabilities for prone position took a left-decubitus position. Two patients in the midazolam group and four patients in the propofol group were counted as a leftdecubitus position. Although there was no statistical difference between the two groups, position of patients might affect cardiopulmonary events.
CONCLUSION
B
OTH MIDAZOLAM AND propofol, together with fentanyl-based endoscopic sedation, in patients over 80 years of age are safe and effective for therapeutic ERCP. Therapeutic outcomes and complications were also not different between the two compounds. In the usual practice of endoscopic sedation without anesthesiologists, propofolbased sedations were more effective than midazolam-based sedations without increasing complications. However, according to the age group, especially for those over 80 years of age, midazolam-based sedation has the same efficacy with a propofol-based sedation. Based on the availability of an antidote and the tendency for sedation safety, midazolambased sedation may be preferred in patients over 80 years of age undergoing non-anesthesiologist-induced sedation. 
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